A clinical case of cardiotoxicity caused by antitumor therapy with osimertinib and bevacizumab

Oncological and cardiovascular diseases are the main causes of mortality worldwide. The rate of these pathologies tends to increase as the population ages. The implementation of highly effective therapeutic schemes has led to a significant increase in the survival rate of oncology patients over the last decades. In many cases, the mortality rate in oncology patients who underwent effective treatment is caused by cardiovascular events arising as a consequence of aggressive antitumor treatment or pre-existing chronic cardiovascular diseases. Among cardiovascular complications that developed both during active treatment of the malignant neoplasm and in the longer term, literature most often mentions cardiac insufficiency.
We present a clinical case of successful diagnosis and treatment of severe heart insufficiency caused by antitumor therapy with bevacizumab and osimertinib in a patient with cancer of the upper lobe of the right lung and metastases into the brain.